# S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC

> **NCT02631460** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 470 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** S1 80-120 mg/d
- **DRUG:** pemetrexed 500 mg/m2
- **DRUG:** carboplatin AUC=5

## Key facts

- **NCT ID:** NCT02631460
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12
- **Primary completion:** 2018-09
- **Final completion:** 2019-12
- **Target enrollment:** 470 (ESTIMATED)
- **Last updated:** 2015-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02631460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02631460, "S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02631460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*